RU2006140257A - Моноклональные антитела к фактору роста гепатоцитов - Google Patents
Моноклональные антитела к фактору роста гепатоцитов Download PDFInfo
- Publication number
- RU2006140257A RU2006140257A RU2006140257/13A RU2006140257A RU2006140257A RU 2006140257 A RU2006140257 A RU 2006140257A RU 2006140257/13 A RU2006140257/13 A RU 2006140257/13A RU 2006140257 A RU2006140257 A RU 2006140257A RU 2006140257 A RU2006140257 A RU 2006140257A
- Authority
- RU
- Russia
- Prior art keywords
- mat according
- hgf
- inhibits
- mab
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (20)
1. Моноклональное антитело (мАт), которое связывается с человеческим фактором роста гепатоцитов (HGF) и нейтрализует его.
2. МАт по п.1, которое является химерным.
3. МАт по п.1, которое является гуманизированным.
4. МАт по п.1, которое является человеческим.
5. МАт по п.1, которое ингибирует связывание HGF с cMet по меньшей мере на 50%.
6. МАт по п.1, которое ингибирует HGF-индуцированное рассеивание клеток почки собаки Madin-Darby.
7. МАт по п.1, которое ингибирует HGF-индуцированную пролиферацию клеток HUVEC.
8. МАт по п.1, которое ингибирует HGF-индуцированный ангиогенез.
9. МАт по п.1, которое нейтрализует все виды биологической активности HGF.
10. МАт по п.1, которое ингибирует рост ксенотрансплантата опухоли человека в мыши.
11. МАт по п.10, которое полностью ингибирует рост ксенотрансплантата опухоли человека в мыши.
12. МАт по п.1, которое представляет собой Fab или F(ab')2 фрагмент или одноцепочечное антитело.
13. МАт по п.1, которое специфически связывается с HGF с показателем аффинности связывания, равным по меньшей мере 108 М-1.
14. Химерное или гуманизированное мАт L2G7.
15. Антитело, которое конкурирует с антителом по п.14 за связывание с человеческим HGF.
16. Клеточная линия, продуцирующая мАт по п.1.
17. Фармацевтическая композиция, содержащая мАт по п.14.
18. Способ лечения рака у пациента, предусматривающий введение пациенту фармацевтической композиции, содержащей нейтрализующее анти-HGF мАт.
19. Способ по п.18, отличающийся тем, что указанный рак представляет собой глиобластому.
20. Способ по п.18, отличающийся тем, что указанное мАт является химерным или гуманизированным мАт L2G7.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/825,060 | 2004-04-15 | ||
| US10/825,060 US20040208876A1 (en) | 2003-04-18 | 2004-04-15 | Monoclonal antibodies to hepatocyte growth factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006140257A true RU2006140257A (ru) | 2008-05-20 |
| RU2361879C2 RU2361879C2 (ru) | 2009-07-20 |
Family
ID=35320045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006140257/13A RU2361879C2 (ru) | 2004-04-15 | 2004-08-13 | Моноклональные антитела к фактору роста гепатоцитов |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20040208876A1 (ru) |
| EP (2) | EP2204191A1 (ru) |
| JP (2) | JP4594381B2 (ru) |
| KR (1) | KR101072736B1 (ru) |
| CN (1) | CN1964738A (ru) |
| AT (1) | ATE473760T1 (ru) |
| AU (1) | AU2004319276C1 (ru) |
| BR (1) | BRPI0418745A (ru) |
| CA (1) | CA2563080C (ru) |
| CR (1) | CR8698A (ru) |
| CY (1) | CY1110783T1 (ru) |
| DE (1) | DE602004028168D1 (ru) |
| DK (1) | DK1734995T3 (ru) |
| ES (1) | ES2346886T3 (ru) |
| HK (1) | HK1094167A1 (ru) |
| HR (1) | HRP20100521T1 (ru) |
| IL (1) | IL178474A (ru) |
| MX (1) | MXPA06011822A (ru) |
| NO (1) | NO20065227L (ru) |
| NZ (1) | NZ550324A (ru) |
| PL (1) | PL1734995T3 (ru) |
| PT (1) | PT1734995E (ru) |
| RU (1) | RU2361879C2 (ru) |
| SI (1) | SI1734995T1 (ru) |
| WO (1) | WO2005107800A1 (ru) |
| ZA (1) | ZA200609407B (ru) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| MEP31408A (en) * | 2003-07-18 | 2010-10-10 | Abgenix Inc | Specific binding agents to hepatocyte growth factor |
| US7476724B2 (en) * | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| EP1885400A4 (en) * | 2005-06-02 | 2011-01-26 | Galaxy Biotech Llc | METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES |
| BRPI0617378B8 (pt) | 2005-10-14 | 2022-09-20 | Chugai Pharmaceutical Co Ltd | Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota |
| AR058135A1 (es) | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| KR20080084818A (ko) * | 2005-11-25 | 2008-09-19 | 각고호우징 게이오기주크 | 전립선암 치료제 |
| EP3135298B1 (en) | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
| AR061171A1 (es) | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch) |
| EP2380908A1 (en) | 2006-06-02 | 2011-10-26 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (hgf) binding proteins |
| WO2008090901A1 (ja) | 2007-01-23 | 2008-07-31 | Shinshu University | 慢性拒絶反応抑制剤 |
| MX2009013886A (es) * | 2007-06-25 | 2010-01-27 | Amgen Inc | Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos. |
| CL2009000843A1 (es) * | 2008-04-11 | 2009-07-24 | Galaxy Biotech Llc | Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet. |
| MX2010012290A (es) * | 2008-05-14 | 2011-02-21 | Amgen Inc | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. |
| JP5544290B2 (ja) | 2008-06-05 | 2014-07-09 | 独立行政法人国立がん研究センター | 神経浸潤抑制剤 |
| PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| US8545839B2 (en) * | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
| CN101555912B (zh) * | 2009-04-29 | 2012-10-03 | 深圳市特辰科技股份有限公司 | 一种转轮式自锁安全制动装置及其工作方法 |
| EP2287197A1 (en) * | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| RS63800B1 (sr) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Poboljšanje antitumorskog odgovora t ćelije |
| JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ |
| JP2013537918A (ja) | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
| KR20140045440A (ko) | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | 항-c-met 항체 제제 |
| CZ303636B6 (cs) * | 2011-08-19 | 2013-01-23 | Invos, Spol. S R. O. | Biokontejner pro sber bioodpadu a komunálního odpadu |
| CN103974720A (zh) | 2011-09-09 | 2014-08-06 | 安姆根有限公司 | C-met蛋白质用于预测抗肝细胞生长因子(“hgf”)抗体在食管癌和胃癌患者中的功效的用途 |
| CA2843771A1 (en) | 2011-09-20 | 2013-03-28 | Eli Lilly And Company | Anti-c-met antibodies |
| US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
| EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| WO2014153117A2 (en) * | 2013-03-14 | 2014-09-25 | Alder Biopharmaceuticals, Inc. | Antibodies to hgf and compositions containing |
| US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
| WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| EP3698808A4 (en) | 2017-10-20 | 2021-07-14 | Hyogo College Of Medicine | MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US722041A (en) * | 1902-11-24 | 1903-03-03 | Mail Belting Company | Conveyer-belt. |
| JP2564486B2 (ja) | 1986-07-14 | 1996-12-18 | 修治 橋本 | 肝細胞増殖因子 |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| GB9003621D0 (en) | 1990-02-16 | 1990-04-11 | Imp Cancer Res Tech | Protein factor |
| GB9009548D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Chimeric antibody and method |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5646036A (en) | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DK0922102T3 (da) * | 1996-07-03 | 2010-08-16 | Genentech Inc | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf |
| WO2000012560A1 (en) | 1998-08-28 | 2000-03-09 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
| US7459536B1 (en) | 1999-11-09 | 2008-12-02 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | HGF-SF monoclonal antibody combinations |
| AU2002355249A1 (en) | 2001-07-26 | 2003-02-17 | Eli Lilly And Company | Interleukin-1 beta antibodies |
| AU2002357388A1 (en) | 2001-12-27 | 2003-07-24 | The United States Of America, As Represented By The Department Of Veterans Affairs | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| AU2003270118A1 (en) * | 2002-08-30 | 2004-03-19 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| CA2528343A1 (en) | 2003-06-06 | 2005-01-06 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
| EP1648493B1 (en) | 2003-07-07 | 2009-12-09 | Van Andel Research Institute | Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor |
| MEP31408A (en) * | 2003-07-18 | 2010-10-10 | Abgenix Inc | Specific binding agents to hepatocyte growth factor |
| KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| EP1885400A4 (en) * | 2005-06-02 | 2011-01-26 | Galaxy Biotech Llc | METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
-
2004
- 2004-04-15 US US10/825,060 patent/US20040208876A1/en not_active Abandoned
- 2004-08-13 NZ NZ550324A patent/NZ550324A/en not_active IP Right Cessation
- 2004-08-13 WO PCT/US2004/026565 patent/WO2005107800A1/en active Application Filing
- 2004-08-13 SI SI200431468T patent/SI1734995T1/sl unknown
- 2004-08-13 KR KR1020067023964A patent/KR101072736B1/ko not_active IP Right Cessation
- 2004-08-13 PT PT04781281T patent/PT1734995E/pt unknown
- 2004-08-13 CA CA2563080A patent/CA2563080C/en not_active Expired - Fee Related
- 2004-08-13 AT AT04781281T patent/ATE473760T1/de active
- 2004-08-13 JP JP2007508323A patent/JP4594381B2/ja not_active Expired - Fee Related
- 2004-08-13 EP EP10160203A patent/EP2204191A1/en not_active Withdrawn
- 2004-08-13 DK DK04781281.3T patent/DK1734995T3/da active
- 2004-08-13 BR BRPI0418745-8A patent/BRPI0418745A/pt not_active IP Right Cessation
- 2004-08-13 PL PL04781281T patent/PL1734995T3/pl unknown
- 2004-08-13 RU RU2006140257/13A patent/RU2361879C2/ru not_active IP Right Cessation
- 2004-08-13 EP EP04781281A patent/EP1734995B1/en not_active Expired - Lifetime
- 2004-08-13 ZA ZA200609407A patent/ZA200609407B/xx unknown
- 2004-08-13 ES ES04781281T patent/ES2346886T3/es not_active Expired - Lifetime
- 2004-08-13 AU AU2004319276A patent/AU2004319276C1/en not_active Ceased
- 2004-08-13 CN CNA200480042750XA patent/CN1964738A/zh active Pending
- 2004-08-13 DE DE602004028168T patent/DE602004028168D1/de not_active Expired - Lifetime
- 2004-08-13 MX MXPA06011822A patent/MXPA06011822A/es active IP Right Grant
-
2006
- 2006-10-05 IL IL178474A patent/IL178474A/en not_active IP Right Cessation
- 2006-10-19 CR CR8698A patent/CR8698A/es unknown
- 2006-11-14 NO NO20065227A patent/NO20065227L/no not_active Application Discontinuation
-
2007
- 2007-02-05 HK HK07101333.7A patent/HK1094167A1/xx unknown
- 2007-02-23 US US11/710,009 patent/US7494650B2/en not_active Expired - Fee Related
- 2007-06-13 US US11/818,305 patent/US7687063B2/en not_active Expired - Fee Related
-
2008
- 2008-12-22 US US12/342,059 patent/US20090104192A1/en not_active Abandoned
-
2010
- 2010-08-03 JP JP2010174810A patent/JP2011012067A/ja not_active Withdrawn
- 2010-08-30 CY CY20101100789T patent/CY1110783T1/el unknown
- 2010-09-22 HR HR20100521T patent/HRP20100521T1/hr unknown
-
2011
- 2011-06-14 US US13/160,444 patent/US20120064066A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006140257A (ru) | Моноклональные антитела к фактору роста гепатоцитов | |
| Lynch et al. | Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment | |
| Jakobovits et al. | From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice | |
| JP6325527B2 (ja) | ヒト化ｐａｎ−ｈｅｒ抗体組成物 | |
| RU2335507C2 (ru) | Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор | |
| RU2006139073A (ru) | Способы лечения боли, обусловленной раком кости, путем введения антагониста фактора роста нервов | |
| ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
| RU2011141890A (ru) | Моноклональные антитела к рецептору 2 фактора роста фибробластов | |
| RU2008143318A (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
| JP2017512765A5 (ru) | ||
| NZ630020A (en) | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof | |
| RU2008137764A (ru) | Способы предотвращения и лечения амилоидных заболеваний | |
| DK1624892T3 (da) | Terapeutisk anvendelse af anti-CSI-antistoffer | |
| RU2016144176A (ru) | Биспецифические антитела к her2 | |
| JP2014527814A5 (ru) | ||
| CN104334580A (zh) | 抗sez6抗体及使用方法 | |
| JP2007536932A5 (ru) | ||
| RS20060234A (en) | Fully human antibodies against human 4-1bb (cd137) | |
| EA200870141A1 (ru) | Комбинационная терапия с использованием антител к egfr и her2 | |
| JP2011521966A5 (ru) | ||
| JP2016006034A (ja) | 塩基性線維芽細胞成長因子に対するモノクローナル抗体 | |
| JP2020522512A5 (ru) | ||
| US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain | |
| JP2020533965A5 (ru) | ||
| WO2003086456A3 (en) | Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160814 |